The optimization method for synthesis of technetium-99m-luteolin as radiotracer in the development of cancer drugs from flavonoid
| Autor: | Maula Eka Sriyani, Danni Ramdhani, S Fairuz Nabila |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
chemistry.chemical_classification
Chromatography Reducing agent Flavonoid Cancer drugs lcsh:RM1-950 radiochemical purity lcsh:RS1-441 010403 inorganic & nuclear chemistry 01 natural sciences radiotracer 0104 chemical sciences technetium-99m-genistein lcsh:Pharmacy and materia medica chemistry.chemical_compound lcsh:Therapeutics. Pharmacology chemistry Yield (chemistry) Original Article Luteolin technetium-99m Technetium-99m |
| Zdroj: | Journal of Advanced Pharmaceutical Technology & Research Journal of Advanced Pharmaceutical Technology & Research, Vol 11, Iss 2, Pp 59-63 (2020) |
| ISSN: | 0976-2094 2231-4040 |
| Popis: | The aim of this study is to find the optimum conditions of labeling luteolin flavonoid compounds with technetium-99m (99mTc) to meet the purity requirements stated in the United States Pharmacopeia. This compound is expected to be a potential radiotracer compound for diagnosing cancer. The optimization method in labeling luteolin with technetium determines the parameters such as pH, SnCl2.2H2O, genistein concentration, and incubation time. Optimization results of Technetium-99m-luteolin labeling obtained optimum pH conditions 8, the amount of SnCl2.2H2O as a reducing agent 60 μL, the optimum amount of luteolin 6 mg/ml, and the optimum incubation time is 30 min. This optimum condition obtained a 99mTc-Luteolin radiochemical purity yield of 94.15%. The radiochemical purity percentage of the 99mTc-Luteolin compound has fulfilled the requirements listed at United States Pharmacopeia, which is ≥90%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |